ABBOTT LABORATORIES (PAKISTAN) LIMITED.
Pharmaceutical company · 196 brands · 201 molecules
Ranked #10 of 74 companies in Pain Management
Company overview
ABBOTT LABORATORIES (PAKISTAN) LIMITED. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 196 product registrations across 201 distinct molecules. It is the 76th largest registrant in Pakistan by product count, and ranks 10th of 74 in Pain Management. Its portfolio is concentrated in Pain Management and Multivitamin, Combinations. DRAP has issued 2 alerts involving its products.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Reported financials
PSX-listed · fiscal year 2024 (Dec 31, 2024)
23% YoY revenue growth, 1900% net profit surge driven by price increases and improved cost management (source: MettisGlobal)
Source: company filing
Products by ABBOTT
157 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.
Price ceiling age
DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.
Top molecules by brand count
Therapeutic classes
Conditions treated
Price band (DRAP official ceilings)
Regulatory record
2 alerts in the DRAP feed we track.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Portfolio whitespace
Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.
Get the full profile for ABBOTT
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included